Nah, it not really for BTA to say... GSK do the marketing but they have other agenda's in mind. They sell direct to governments, if they came out and said Relenza sales were booming then the press would have a field day. Quarterly reports are just fine... keep the revenue low key.
Only a few more trading days before we see the news... we must also be coming close to LANI application for marketing, and ROW license deal.
Ahh, the calm before the storm :)
BTA Price at posting:
$2.00 Sentiment: Buy Disclosure: Held
